Lung cancer (non-small cell)
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where to go
6 hospitals in India taking patients for this trial.
Registry summary (technical)
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Sponsor: Daiichi Sankyo
NCT06899126 on ClinicalTrials.gov
Last updated on the registry 15 Sep 2026 · read by us 20 Oct 2026